Koninklijke DSM N.V.
http://www.dsm.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Koninklijke DSM N.V.
How Did US FDA Get Octapharma To Drop Its Suit?
Company sought court order to vacate agency’s approval of the fibrinogen products of three blood centers, saying they were wrongly exempt from clinical trials required for Octapharma’s Fibryga.
Grifols Aims For Largely Untapped Market With Successful Fibrinogen Deficiency Study
The Phase III trial of BT524 produced positive topline results in patients with acquired fibrinogen deficiency, potentially making it the first fibrinogen concentrate to win US FDA approval for that indication.
FDA’s Disparate Treatment Of Fibrinogen Products ‘Defies Logic,’ Octapharma Contends
Suit says FDA wrongly classified the fibrinogen products of three blood centers as ‘blood components’ exempt from clinical trials while classifying Octapharma’s Fibryga as a ‘blood derivative’ subject to clinical studies.
P&G Ventures Startup Incubator Yields Supplements For Menopause Symptoms
P&G Ventures startup's partnership with venture capital group M13 delivered its first brand, the Kindra four-product, hormone-free menopausal line. Kindra says its products provide relief from the seven symptoms of menopause in a market largely neglected.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Nutraceuticals
- OTC, Consumer
- Other Names / Subsidiaries
-
- Aland (HK) Holding Limited
- Amyris Brasil Ltda
- BioCare Copenhagen
- DSM Biomedical
- Fortitech, Inc.
- Glycom A/S
- Kensey Nash Corporation
- Koninklijke CSK Food Enrichment C.V.
- Royal DSM N.V.
- Tortuga Companhia Zootecnica Agraria
- Unitech Industries Limited
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice